SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, announced that it presented data on its oncology program at The 8th Annual Meeting of the International Society of Geriatric Oncology being held in Madrid, Spain, November 8 – 10, 2007. Findings presented at the conference suggest that Hollis-Eden’s drug candidate APOPTONE™ (HE3235) and other compounds from the Company’s hormonal signaling technology platform may play a role in treating or preventing diseases associated with aging, including hormone receptor-sensitive cancers.
